Jones Healthcare & Technology Innovation Conference: Wave CEO Paul Bolno discusses recent DMD data and regulatory feedback, and shares updates on alpha-1 antitrypsin, obesity, and Huntington's
- Apr 9, 2025
- 1 min read
He describes the 48 week data for the exon 53 DMD program, and discusses the company's plan to seek accelerated approval. Plus, guidance on when to expect clinical updates on other programs.
Brought to you by:
.png){kind=logo}